CCXI ChemoCentryx, Inc. Stock Quote

CCXI [NASD]

Index	-	P/E	-	EPS (ttm)	-1.89	Insider Own	4.20%	Shs Outstand	71.23M	Perf Week	0.94%
Market Cap	3.69B	Forward P/E	-	EPS next Y	-0.22	Insider Trans	-6.74%	Shs Float	62.26M	Perf Month	1.20%
Income	-133.10M	PEG	-	EPS next Q	-0.38	Inst Own	84.00%	Short Float	11.10%	Perf Quarter	104.45%
Sales	37.30M	P/S	98.93	EPS this Y	-123.80%	Inst Trans	4.91%	Short Ratio	2.92	Perf Half Y	113.25%
Book/sh	3.32	P/B	15.51	EPS next Y	59.10%	ROA	-30.60%	Target Price	52.00	Perf Year	225.74%
Cash/sh	4.59	P/C	11.23	EPS next 5Y	-	ROE	-48.50%	52W Range	14.95 - 51.78	Perf YTD	41.44%
Dividend	-	P/FCF	-	EPS past 5Y	-17.00%	ROI	-41.90%	52W High	-0.37%	Beta	1.24
Dividend %	-	Quick Ratio	4.50	Sales past 5Y	22.00%	Gross Margin	96.50%	52W Low	245.08%	ATR	1.12
Employees	178	Current Ratio	4.50	Sales Q/Q	555.60%	Oper. Margin	-	RSI (14)	84.19	Volatility	0.68% 0.60%
Optionable	Yes	Debt/Eq	0.10	EPS Q/Q	20.90%	Profit Margin	-	Rel Volume	0.46	Prev Close	51.50
Shortable	Yes	LT Debt/Eq	0.02	Earnings	Aug 09 AMC	Payout	-	Avg Volume	2.37M	Price	51.59
Recom	1.60	SMA20	1.07%	SMA50	39.96%	SMA200	74.22%	Volume	217,877	Change	0.17%

Aug-04-22

Resumed

Canaccord Genuity

Buy

$81

Oct-11-21

Upgrade

SVB Leerink

Mkt Perform → Outperform

$64

Oct-11-21

Upgrade

JP Morgan

Underweight → Neutral

$14 → $38

Oct-08-21

Upgrade

Raymond James

Outperform → Strong Buy

$62 → $107

Oct-08-21

Upgrade

Piper Sandler

Neutral → Overweight

Jul-07-21

Upgrade

Stifel

Hold → Buy

$26 → $31

May-07-21

Downgrade

SVB Leerink

Outperform → Mkt Perform

May-07-21

Downgrade

Stifel

Buy → Hold

$93 → $26

May-07-21

Downgrade

Raymond James

Strong Buy → Outperform

May-07-21

Downgrade

Piper Sandler

Overweight → Neutral

$80 → $25

May-07-21

Downgrade

JP Morgan

Neutral → Underweight

$57 → $17

Mar-02-21

Reiterated

H.C. Wainwright

Buy

$83 → $101

Mar-02-21

Initiated

Stifel

Buy

$93

Oct-29-20

Downgrade

JP Morgan

Overweight → Neutral

$63 → $60

Jun-17-20

Initiated

BTIG Research

Buy

$70

May-27-20

Initiated

Wells Fargo

Overweight

$79

May-12-20

Reiterated

H.C. Wainwright

Buy

$60 → $69

Jan-24-20

Reiterated

H.C. Wainwright

Buy

$40 → $60

Nov-26-19

Reiterated

Piper Jaffray

Overweight

$17 → $54

Nov-26-19

Reiterated

H.C. Wainwright

Buy

$23 → $40

Sep-07-22 11:30AM	Why Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report? Zacks
Sep-01-22 10:59AM	How Covid, 'industrial logic' and a threat played out in a multibillion-dollar biotech merger American City Business Journals
Aug-29-22 08:00AM	These 10 Non-Covid Biotech Stocks Are Up 40% Or More This Year Investor's Business Daily
Aug-24-22 08:30AM	ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences GlobeNewswire
Aug-16-22 12:00PM	Here's Why ChemoCentryx (CCXI) is a Great Momentum Stock to Buy Zacks
09:55AM	ChemoCentryx (CCXI) Now Trades Above Golden Cross: Time to Buy? Zacks
Aug-15-22 10:35AM	Amgen Inc. -- Moody's assigns Baa1 rating to Amgen's notes; stable outlook Moody's
Aug-12-22 06:05AM	The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals Zacks
Aug-09-22 08:30AM	ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call GlobeNewswire
Aug-05-22 05:16PM	Amgen Narrows Sales Outlook Following Plans To Acquire ChemoCentryx Investor's Business Daily
09:45AM	Amgen (AMGN) Beats Q2 Earnings Estimates, to Buy Chemocentryx Zacks
07:29AM	ChemoCentryx (CCXI) Moves 109.2% Higher: Will This Strength Last? Zacks
Aug-04-22 07:10PM	ChemoCentrix Spikes 110% on Amgen Acquisition Deal GuruFocus.com +109.17%
05:23PM	Amgen to buy ChemoCentryx for billions in cash American City Business Journals
04:18PM	Amgen Aims To Stanch Generic Losses With $3.7 Billion ChemoCentryx Buyout Investor's Business Daily
11:35AM	Amgen Acquires Drugmaker ChemoCentryx for $3.7 Billion Barrons.com
11:16AM	Big biotech to buy one-drug Peninsula company ChemoCentryx for $3.7 billion cash American City Business Journals
10:08AM	Why ChemoCentryx Stock Is On Fire Today Motley Fool
10:00AM	Will Brickell (BBI) Report Negative Earnings Next Week? What You Should Know Zacks
09:05AM	ChemoCentryx Stock More Than Doubles On $4B Buyout Benzinga
08:24AM	Amgen to gain rare-disease drug in $3.7 billion acquisition of ChemoCentryx MarketWatch
08:17AM	Amgen bets on ChemoCentryx's rare disease drug in $3.7 billion deal Reuters
08:15AM	UPDATE 4-Amgen bets on ChemoCentryx's rare disease drug in $3.7 bln deal Reuters
08:00AM	Amgen to Buy ChemoCentryx for $3.7 Billion The Wall Street Journal
08:00AM	AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH PR Newswire
Aug-02-22 04:05PM	ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022 GlobeNewswire
Jul-14-22 11:15AM	ChemoCentryx Stock Shows Market Leadership With Jump To 81 RS Rating Investor's Business Daily
Jul-06-22 12:42PM	ChemoCentryx, Inc.'s (NASDAQ:CCXI) Path To Profitability Simply Wall St. -5.66%
Jul-05-22 12:53PM	ChemoCentryx's (CCXI) Tavneos Aids Growth, Overdependence a Woe Zacks
08:30AM	ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director GlobeNewswire
Jun-09-22 11:30AM	Catalyst (CPRX) Up 6.9% Since Last Earnings Report: Can It Continue? Zacks
Jun-06-22 12:21PM	The five-year returns have been stellar for ChemoCentryx (NASDAQ:CCXI) shareholders despite underlying losses increasing Simply Wall St.
08:30AM	ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-31-22 04:05PM	ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences GlobeNewswire
08:30AM	ChemoCentryx Announces Changes to its Board of Directors GlobeNewswire
May-18-22 08:30AM	ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa GlobeNewswire
May-16-22 08:30AM	ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference GlobeNewswire
May-11-22 08:30AM	ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis GlobeNewswire -7.83%
May-06-22 03:38PM	ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates Zacks +11.13%
May-05-22 06:35PM	ChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates Zacks -7.95%
04:05PM	ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights GlobeNewswire
Apr-28-22 03:02PM	Will ChemoCentryx (CCXI) Report Negative Q1 Earnings? What You Should Know Zacks
08:30AM	ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022 GlobeNewswire
Apr-19-22 09:13AM	Is ChemoCentryx (NASDAQ:CCXI) Weighed On By Its Debt Load? Simply Wall St.
Apr-13-22 08:30AM	ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022 GlobeNewswire
Mar-31-22 11:30AM	Why Is ChemoCentryx (CCXI) Up 1.8% Since Last Earnings Report? Zacks
Mar-30-22 11:30AM	2 Stocks Down 30% in 2022 That Are Great Buys Right Now Motley Fool
Mar-07-22 08:43AM	Is ChemoCentryx, Inc. (CCXI) A Great Long-Term Investment? Insider Monkey
Mar-05-22 06:08AM	ChemoCentryx, Inc.'s stock is down 24%, but insiders still have about US$133k in profit after buying earlier this year Simply Wall St.
Mar-02-22 01:51PM	See Why Is Stifel Analyst 'Perplexed' After ChemoCentryx Q4 Earnings Benzinga -16.67%
10:33AM	ChemoCentryx (CCXI) Q4 Earnings and Sales Miss Estimates Zacks
Mar-01-22 05:35PM	ChemoCentryx (CCXI) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:05PM	ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights GlobeNewswire
Feb-23-22 08:30AM	ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 1, 2022 GlobeNewswire
Feb-09-22 08:30AM	ChemoCentryx to Participate in the 11th Annual SVB Leerink Global Healthcare Conference GlobeNewswire +8.71%
Feb-08-22 03:25PM	Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates Zacks
Feb-04-22 09:38AM	Lisanti Capital Growth, LLC Buys Saia Inc, Knight-Swift Transportation Holdings Inc, ... GuruFocus.com
Jan-20-22 11:31AM	ChemoCentryx (CCXI) Tavneos Gets EU Nod for ANCA Vasculitis Zacks -9.66%
Jan-19-22 10:47AM	ChemoCentryx's Avacopan Scores European Approval For ANCA-Associated Vasculitis Benzinga
08:30AM	ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis GlobeNewswire
Jan-18-22 08:22PM	Wells Fargo Pounds the Table on ChemoCentryx Stock TipRanks -5.54%
Jan-12-22 10:30AM	Why ChemoCentryx Stock Tanked in 2021 Motley Fool -5.41%
Jan-07-22 05:22AM	When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Breakeven? Simply Wall St. -6.44%
Jan-04-22 08:30AM	ChemoCentryx to Present at Two Upcoming Investor Conferences GlobeNewswire +5.16%
Jan-03-22 06:04AM	3 Biotech Stocks That Could Double in 2022 Motley Fool
Dec-27-21 07:19AM	ChemoCentryx's (CCXI) Stock Increases on Tavneos' FDA Nod Zacks
Nov-23-21 05:18AM	ChemoCentryx's (NASDAQ:CCXI) investors will be pleased with their incredible 382% return over the last five years Simply Wall St.
Nov-15-21 11:12AM	ChemoCentryx (CCXI) Gets Positive CHMP Opinion for Tavneos Zacks
Nov-12-21 08:30AM	Positive Recommendation for Use of TAVNEOS (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) GlobeNewswire
Nov-10-21 10:44AM	ChemoCentryx (CCXI) Q3 Loss Narrower Than Expected, Sales Top Zacks
08:00AM	ChemoCentryx to Participate in Two Upcoming Investor Conferences GlobeNewswire
06:20AM	Big Pharma Is Going Holiday Shopping. Who's Next? Motley Fool
01:01AM	ChemoCentryx, inc (CCXI) Q3 2021 Earnings Call Transcript Motley Fool
Nov-09-21 05:55PM	ChemoCentryx (CCXI) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM	ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights GlobeNewswire
Nov-08-21 09:29AM	Should You Buy ChemoCentryx (CCXI) Ahead of Earnings? Zacks
Nov-04-21 08:30AM	Abstracts at the Annual Meetings of the American Society of Nephrology and American College of Rheumatology Highlight Potential Value of TAVNEOS (avacopan) GlobeNewswire
Nov-02-21 08:30AM	ChemoCentryx to Hold Third Quarter 2021 Financial Results Conference Call on Tuesday, November 9, 2021 GlobeNewswire
Nov-01-21 03:01PM	ChemoCentryx (CCXI) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Oct-14-21 07:18AM	Is It Too Late to Buy ChemoCentryx Stock? Motley Fool
Oct-13-21 10:00AM	2 Super-Charged Growth Stocks to Buy Now Motley Fool
Oct-11-21 07:43PM	3 Strong Buy Stocks Raymond James Predicts Will Rally Over 60% TipRanks +5.44%
08:38AM	Company News for Oct 11, 2021 Zacks
08:30AM	ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer GlobeNewswire
04:21AM	5 Stocks To Watch For October 11, 2021 Benzinga
02:27AM	ChemoCentryx Receives FDA Approval for TAVNEOS; Shares Skyrocket SmarterAnalyst
Oct-09-21 09:19AM	Is ChemoCentryx, Inc. (NASDAQ:CCXI) Trading At A 41% Discount? Simply Wall St.
Oct-08-21 05:57PM	After half-billion dollars, nearly quarter century, Peninsula biotech lands its first FDA drug approval American City Business Journals +95.97%
05:40PM	Why ChemoCentryx Stock Skyrocketed Today Motley Fool
04:26PM	ChemoCentryx Up Most Since 2019 on Autoimmune Drug Approval Bloomberg
02:50PM	Sundial Growers stock rises, ChemoCentryx soars as Home Depot & Lowe's shares slip Yahoo Finance Video
02:36PM	Mid-Afternoon Market Update: Dow Surges 80 Points; ChemoCentryx Shares Spike Higher Benzinga
01:10PM	ChemoCentryx, Allogene Show the Risks and Rewards of Nasdaq Biotech Stocks Motley Fool
12:53PM	ChemoCentryx Shares Are Spiking After an Unexpected FDA Approval Barrons.com
12:20PM	EXCLUSIVE: ChemoCentryx Plans To Start Phase 3 Avacopan Trial In Chronic Skin Disorder In 2022 Benzinga
12:05PM	ChemoCentryx (CCXI) Tavneos Gets FDA Nod for ANCA Vasculitis Zacks
12:03PM	28 Stocks Moving In Friday's Mid-Day Session Benzinga
08:24AM	ChemoCentryx's stock jumps 80% after receiving FDA approval for vasculitis drug MarketWatch
08:04AM	5 Top Stock Gainers for Friday: ChemoCentryx, Plug Power, Quidel TheStreet.com
07:28AM	UPDATE 3-ChemoCentryx's drug gets U.S. FDA nod for treating rare autoimmune disease Reuters

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KANAYA SUSAN M	EVP, CFO and Sec.	Aug 16	Option Exercise	10.86	19,898	216,092	111,215	Aug 18 04:48 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Aug 16	Sale	50.95	19,898	1,013,793	91,317	Aug 18 04:48 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Aug 04	Option Exercise	6.50	46,298	300,805	137,615	Aug 08 07:33 PM
Schall Thomas J.	President and CEO	Aug 04	Option Exercise	14.28	130,000	1,856,400	2,523,352	Aug 08 07:41 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Aug 04	Sale	50.22	7,564	379,864	87,658	Aug 08 07:21 PM
Schall Thomas J.	President and CEO	Aug 04	Sale	50.24	130,000	6,531,733	2,393,352	Aug 08 07:41 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Aug 04	Sale	50.17	46,298	2,322,715	91,317	Aug 08 07:33 PM
Tyree James L	Director	Aug 04	Sale	50.22	10,000	502,200	9,138	Aug 08 07:27 PM
Tyree James L	Director	Jun 09	Sale	25.66	3,863	99,129	19,138	Jun 13 06:28 PM
Tyree James L	Director	May 20	Option Exercise	0.00	7,726	0	23,001	May 24 08:18 PM
Parker Geoffrey M.	Director	May 20	Option Exercise	0.00	7,726	0	21,076	May 24 08:13 PM
MCKINNELL HENRY A	Director	May 20	Option Exercise	0.00	7,726	0	72,749	May 24 07:34 PM
Jain Rita	EVP, Chief Medical Officer	May 20	Option Exercise	0.00	7,726	0	35,863	May 24 07:27 PM
Parker Geoffrey M.	Director	May 02	Option Exercise	14.42	12,500	180,250	124,413	May 03 10:29 AM
Jain Rita	EVP, Chief Medical Officer	Mar 27	Option Exercise	0.00	5,251	0	28,137	Mar 29 07:50 PM
FECZKO JOSEPH M	Director	Jan 21	Option Exercise	15.41	37,500	577,750	148,127	Jan 25 08:03 PM
Schall Thomas J.	President and CEO	Jan 01	Option Exercise	0.00	84,234	0	2,439,050	Jan 04 09:42 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Jan 01	Option Exercise	0.00	30,799	0	149,564	Jan 04 09:38 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Jan 01	Option Exercise	0.00	20,934	0	106,760	Jan 04 09:35 PM
Tyree James L	Director	Dec 17	Option Exercise	13.22	37,500	495,750	52,775	Dec 21 06:33 PM
Tyree James L	Director	Dec 17	Sale	35.02	37,500	1,313,165	15,275	Dec 21 06:33 PM
Schall Thomas J.	President and CEO	Dec 01	Option Exercise	10.88	45,936	499,994	2,354,816	Dec 03 07:39 PM
Vifor (International) Ltd	10% Owner	Oct 12	Sale	39.43	4,000,000	157,720,000	5,194,085	Oct 13 07:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience